Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
TEVAPHARMIND SP ADR (NY: TEVA)
21.09 USD  -0.14 (-0.66%)
Official Closing Price  /  Updated: 8:04 PM EDT, May 21, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 8,690,912
Open 21.49
Bid (Size) 21.06 (300)
Ask (Size) 21.08 (1000)
Prev. Close 21.23
Today's Range 20.94 - 21.49
52wk Range 10.85 - 33.82
Shares Outstanding 1,016,290,682
Dividend Yield 5.64%
Performance
YTD
+10.36%
+10.36%
1 Month
+18.15%
+18.15%
3 Month
+5.56%
+5.56%
6 Month
+61.24%
+61.24%
1 Year
-28.36%
-28.36%
Top News
More News
CORRECTING and REPLACING Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
First bulleted paragraph, second sentence of release dated May 15, 2018 should contain the numbers 4.9, 5.3 and 6.5 (instead of 4.6, 4.9 and 5.9, respectively). Third bulleted paragraph, second... Read More
from Business Wire News Releases
Amgen Wins Race To Migraine Prevention Drug — Lilly, Teva, Alder Trail
Amgen was first to the finish line late Thursday with a drug designed to prevent chronic migraines by blocking a specific receptor — leading Lilly, Teva and Alder. Read More
from Investor's Business Daily
More News
Read More
Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
category Health Care/Pharmaceuticals Biotechnology and Life Sciences/Pharmaceuticals , Politics and Government/Government Agencies/FDA , Prescription drug costs , and 20 more.
from CNBC.com News
Premarket Mixed, Dow Jones Lags; Boot Barn Poised For Gap Up Open
from Investor's Business Daily
UPDATE 1-Hikma reaffirms full-year revenue forecast, cites better generics business
category companyNews
from Reuters: Company News
UPDATE 4-U.S. FDA approves Amgen drug for prevention of migraines
category companyNews
from Reuters: Company News
CORRECTED-UPDATE 3-U.S. FDA approves Amgen drug for prevention of migraines
category companyNews
from Reuters: Company News
UPDATE 2-U.S. FDA approves Amgen drug for prevention of migraines
category companyNews
from Reuters: Company News
Buffett Gets Even Greedier With Teva Pharmaceuticals. Time to Buy?
category BRK/B , TEVA , Market News , and 1 more.
from Motley Fool
UPDATE 1-U.S. FDA approves Amgen drug for prevention of migraines
category companyNews
from Reuters: Company News
U.S. FDA approves Amgen migraine drug, price set at $6900/yr
category companyNews
from Reuters: Company News
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial